Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: Possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 7, 2010, Pages 908-914

  Choi, Dong Hyun ^a   Li, Cheng ^a,b   Choi, Jun Shik ^a  

^a Chosun University   (South Korea)

^b YANBIAN UNIVERSITY   (China)

Author keywords

cytochrome P450 enzymes; EXP 3174; losartan; myricetin; P glycoprotein

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLYCOPROTEIN P; LOSARTAN; MYRICETIN; RHODAMINE 123;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; ENZYME ACTIVITY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT;

ANIMALS; ANTIOXIDANTS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FLAVONOIDS; HERB-DRUG INTERACTIONS; IMIDAZOLES; LOSARTAN; MALE; P-GLYCOPROTEIN; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES;

EID: 77954022331     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.07.0012     Document Type: Article

References (36)

1. Diez J. Review of the molecular pharmacology of losartan and its possible relevance to stroke prevention in patients with hypertension. Clin Ther 2006 28 : 832 848.
2. McIntyre M et al. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997 74 : 181 194.
3. Inagami T et al. Cloning, expression and regulation of angiotensin II receptors. J Hypertens 1992 8 : 713 716.
4. Lo MW et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995 58 : 641 649.
5. Wong PC et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990 255 : 211 217.
6. Stearns RA et al. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab Dispos 1992 20 : 281 287.
7. Yun CH et al. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos 1995 23 : 285 289.
8. Meadowcroft AM et al. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999 39 : 418 424.
9. Kaukonen KM et al. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998 53 : 445 449.
10. McCrea JB et al. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther 1999 65 : 348 352.
11. Soldner A et al. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCKMDR1 and caco-2 cell monolayers. Br J Pharmacol 2000 129 : 1235 1243.
12. Zaidenstein R et al. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit 2001 23 : 369 373.
13. Kobayashi M et al. The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Drug Metab Pharmacokinet 2008 23 : 115 119.
14. Chung JH et al. Effect of epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. Biopharm Drug Dispos 2009 30 : 90 93.
15. Piao YJ et al. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats. Arch Pharm Res 2008 31 : 518 522.
16. Choi JS et al. Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacol Res 2005 52 : 386 391.
17. Cho YA et al. Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. J Pharm Pharmacol 2009 61 : 825 829.
18. Dixon RA et al. Flavonoids and isoflavonoids - a gold mine for metabolic engineering. Trends Plant Sci 1999 4 : 394 400.
19. Middleton E Jr. et al. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000 52 : 673 751.
20. Xue B et al. Effect of total flavonoid fraction of Astragalus complanatus R. Brown on angiotensin II-induced portal-vein contraction in hypertensive rats. Phytomedicine 2008 15 : 759 762.
21. German JB et al. The health benefits of wine. Annu Rev Nutr 2000 20 : 561 593.
22. Hakkinen SH et al. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J Agric Food Chem 1999 47 : 2274 2279.
23. Nishijima CM et al. Anti-hemorrhagic activity of four Brazilian vegetable species against Bothrops jararaca venom. Molecules 2009 14 : 1072 1080.
24. Tiwari R et al. Cardioprotective potential of myricetin in isoproterenol-induced myocardial infarction in Wistar rats. Phytother Res 2009 23 : 1361 1366.
25. Von Moltke LL et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 2004 56 : 1039 1044.
26. Václavíková R et al. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch Pharmacol 2003 368 : 200 209.
27. Kitagawa S et al. Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull 2005 28 : 2274 2278.
28. Zarghi A et al. A rapid HPLC method for the determination of losartan in human plasma using a monolithic column. Arzneimittelforschung 2005 55 : 569 572. (Pubitemid 41546101)
29. Crespi CL et al. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 1997 248 : 188 190.
30. Benet LZ et al. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003 4 : 393 398.
31. Cummins CL et al. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002 300 : 1036 1045.
32. Kelly PA et al. Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 1999 24 : 321 328.
33. Cao X et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 2006 23 : 1675 1686.
34. Piao YJ et al. Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats. J Pharm Pharmacol 2008 60 : 625 629.
35. Krieter PA et al. Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine. J Pharmacol Exp Ther 1995 273 : 816 822.
36. Stearns RA et al. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995 23 : 207 215.